We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+0.37%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.56B
AUM Growth
-$92.1M
(-5.6%)
Cap. Flow
-$16.4M
Cap. Flow
% of AUM
-1.05%
Top 10 Holdings %
Top 10 Hldgs %
77.78%
Holding
44
New
2
Increased
8
Reduced
7
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$19.5M |
| 2 |
eHealth
EHTH
|
+$15.6M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
+$6.86M |
| 4 |
Biogen
BIIB
|
+$6.02M |
| 5 |
Alkermes
ALKS
|
+$4.32M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
+$17.3M |
| 2 |
Vanda Pharmaceuticals
VNDA
|
+$16.7M |
| 3 |
ABMD
Abiomed Inc
ABMD
|
+$10.4M |
| 4 |
AstraZeneca
AZN
|
+$10.1M |
| 5 |
Puma Biotechnology
PBYI
|
+$9.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.34% |
| 2 | Financials | 2.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$13.5B
| $196M | 12.49% |
2,212,950
| – | – |
|
|
ABMD
2
DELISTED
Abiomed Inc
ABMD
| $186M | 11.91% |
519,033
-30,787
| -6% | -$10.4M |
|
3
Insmed
INSM
$28.8B
| $164M | 10.49% |
6,025,706
+6,600
| +0.1% | +$189K |
|
4
United Therapeutics
UTHR
$22B
| $148M | 9.49% |
687,206
| – | – |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $117M | 7.47% |
10,114,043
| – | – |
|
6
STAAR Surgical
STAA
$1.26B
| $104M | 6.65% |
1,140,511
| – | – |
|
|
7
Biogen
BIIB
$30.4B
| $92.4M | 5.9% |
385,000
+23,400
| +6% | +$6.02M |
|
8
Prothena Corp
PRTA
$474M
| $83.3M | 5.32% |
1,685,282
| – | – |
|
|
RVNC
9
DELISTED
Revance Therapeutics, Inc.
RVNC
| $71.3M | 4.56% |
4,369,366
+1,167,500
| +36% | +$19.5M |
|
10
Acadia Pharmaceuticals
ACAD
$5.06B
| $54.6M | 3.49% |
2,337,877
| – | – |
|
|
11
Vanda Pharmaceuticals
VNDA
$294M
| $44.5M | 2.84% |
2,834,244
-957,561
| -25% | -$16.7M |
|
|
12
eHealth
EHTH
$39.1M
| $41.2M | 2.63% |
1,615,570
+469,700
| +41% | +$15.6M |
|
13
Align Technology
ALGN
$12.4B
| $36.4M | 2.33% |
55,405
| – | – |
|
14
Karyopharm Therapeutics
KPTI
$49.2M
| $35.2M | 2.25% |
364,697
+5,827
| +2% | +$581K |
|
|
SAGE
15
DELISTED
Sage Therapeutics
SAGE
| $33.3M | 2.13% |
781,730
+163,800
| +27% | +$6.86M |
|
|
GRTS
16
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $30.3M | 1.94% |
2,356,282
| – | – |
|
17
Gossamer Bio
GOSS
$89.4M
| $20.1M | 1.28% |
1,772,950
| – | – |
|
|
18
Alkermes
ALKS
$8.28B
| $17.5M | 1.12% |
754,200
+164,300
| +28% | +$4.32M |
|
19
AnaptysBio
ANAB
$1.68B
| $15.2M | 0.97% |
436,592
| – | – |
|
|
EPZM
20
DELISTED
Epizyme, Inc
EPZM
| $13.7M | 0.88% |
5,485,213
-1,371,300
| -20% | -$5.39M |
|
21
Syndax Pharmaceuticals
SNDX
$1.8B
| $13.1M | 0.84% |
598,900
+154,000
| +35% | +$2.85M |
|
|
KZR
22
DELISTED
Kezar Life Sciences
KZR
| $11M | 0.7% |
65,620
| – | – |
|
|
CLVS
23
DELISTED
Clovis Oncology, Inc.
CLVS
| $10.8M | 0.69% |
3,997,826
-486,585
| -11% | -$1.8M |
|
24
Cytokinetics
CYTK
$10.7B
| $5.64M | 0.36% |
123,686
| – | – |
|
25
Travere Therapeutics
TVTX
$5.72B
| $5.16M | 0.33% |
166,069
| – | – |
|
Similar funds
RRA
AG
BL
CG
GAMA
PIM
ACA
RK
Palo Alto Investors's Q4 2021 Portfolio in Review
As of Q4 2021, Palo Alto Investors held 44 positions worth $1.56B, down 5.6% from $1.66B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Palo Alto Investors's Q4 2021 filing shows 2 new, 8 increased, 7 reduced and 7 closed positions. Its largest new stake was Novavax: 12,500 shares worth $1.79M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $17.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.
- Palo Alto Investors's largest Q4 2021 buy was Novavax: 12,500 shares worth $1.79M.
- Palo Alto Investors added most to Revance Therapeutics, Inc. in Q4 2021, an estimated $19.5M increase.
- Palo Alto Investors's biggest Q4 2021 reduction was Vanda Pharmaceuticals, cutting an estimated $16.7M.
- Palo Alto Investors fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $17.3M.
- Palo Alto Investors's ten largest holdings make up 78% of its $1.56B portfolio in Q4 2021.
- Palo Alto Investors opened 2 new positions and closed 7 in Q4 2021.
- Palo Alto Investors's portfolio value fell 5.6% quarter-over-quarter to $1.56B.
Based on Palo Alto Investors's 13F filing for Q4 2021, filed 14 Feb 2022.